Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Vilaseca

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Transplantation Direct|July 8, 2026
Quality Assessment of Discarded Human Kidneys Using Normothermic PerfusionEnrique Montagud-Marrahi, Thomas Prudhomme, Tarek Ajami, et al.
European Urology Open Science|April 30, 2026
PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world EvidenceAna Guijarro, Estíbaliz Jiménez, Antoni Vilaseca, et al.
European Urology Focus|June 20, 2021
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic ReviewLisa Moris, Giorgio Gandaglia, Antoni Vilaseca, et al.
European Urology Open Science|November 29, 2024
AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer Management by the OPTIMA ConsortiumVasileios Sakalis, Yagnaseni Bhattacharya, Katharina Beyer, et al.
European Urology Open Science|October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world DatabaseMario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
The Prostate|September 4, 2025
Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With ApalutamideChristian Andrés Martínez Osorio, Raquel Sopeña Sutil, Antoni Vilaseca Cabo, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Transplantation Direct|July 8, 2026
Quality Assessment of Discarded Human Kidneys Using Normothermic PerfusionEnrique Montagud-Marrahi, Thomas Prudhomme, Tarek Ajami, et al.
European Urology Open Science|April 30, 2026
PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world EvidenceAna Guijarro, Estíbaliz Jiménez, Antoni Vilaseca, et al.
European Urology Focus|June 20, 2021
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic ReviewLisa Moris, Giorgio Gandaglia, Antoni Vilaseca, et al.
European Urology Open Science|November 29, 2024
AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer Management by the OPTIMA ConsortiumVasileios Sakalis, Yagnaseni Bhattacharya, Katharina Beyer, et al.
European Urology Open Science|October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world DatabaseMario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
The Prostate|September 4, 2025
Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With ApalutamideChristian Andrés Martínez Osorio, Raquel Sopeña Sutil, Antoni Vilaseca Cabo, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 5